作者
Amanda L Wilkinson, Khalequ Zaman, Masuma Hoque, Concepcion F Estivariz, Cara C Burns, Jennifer L Konopka-Anstadt, Bernardo A Mainou, Stephanie D Kovacs, Qian An, Jacquelyn S Lickness, Mohammad Yunus, Cynthia J Snider, Yiting Zhang, Elizabeth Coffee, Talha Abid, Steven GF Wassilak, Mark A Pallansch, M Steven Oberste, John F Vertefeuille, Abhijeet Anand
发表日期
2023/9/1
期刊
The Lancet Infectious Diseases
卷号
23
期号
9
页码范围
1062-1071
出版商
Elsevier
简介
Background
Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine-derived poliovirus type 2 outbreaks. Bivalent oral poliovirus vaccine (bOPV; containing Sabin types 1 and 3) is the vaccine of choice for type 1 and type 3 outbreak responses. We aimed to assess immunological interference between nOPV2 and bOPV when administered concomitantly.
Methods
We conducted an open-label, non-inferiority, randomised, controlled trial at two clinical trial sites in Dhaka, Bangladesh. Healthy infants aged 6 weeks were randomly assigned (1:1:1) using block randomisation, stratified by site, to receive nOPV2 only, nOPV2 plus bOPV, or bOPV only, at the ages of 6 weeks, 10 weeks, and 14 weeks. Eligibility criteria included singleton and full term (≥37 weeks' gestation) birth and parents intending to remain in …
学术搜索中的文章
AL Wilkinson, K Zaman, M Hoque, CF Estivariz… - The Lancet Infectious Diseases, 2023